HURA TuHURA Biosciences, Inc./NV

NEUTRAL Impact: 4/10 8-K
Horizon days Filed May 29, 2026 Processed 11d 12h ago SEC 0001193125-26-248640
8-K context-dependent: Items 2.03
Latest settled — T+5d
HURA ▼ -12.28% at T+5d
NEUTRAL call ✗ call lost -12.28% · α vs SPY -9.53% · entry $2.24 → $1.97
Next anchor: T+20d in 19d
Last close $2.05 (close Jun 8) · -8.71% from $2.24 entry
Entry anchored
May 29, 2026
via day open
T+1d
-2.68%
call -2.68% · α -2.82%
$2.18
settled 9d ago
T+5d
-12.28%
call -12.28% · α -9.53%
$1.97
settled 5d ago
T+20d
call — · α —
in 19d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

TuHURA Biosciences drew $1.7M from its $50M revolving credit facility with Parkview Holdings One LLC, the first draw under the facility that matures April 2026. The minimal initial draw relative to the $50M capacity and use for general corporate purposes suggest modest near-term cash needs, but the existence of a large undrawn facility and related-party lender (affiliate of largest stockholder) introduce lingering capital structure and conflict-of-interest considerations.

Actionable Insight

Monitor for additional draws under the facility, which would signal accelerating cash burn. The large undrawn $48.3M capacity plus the related-party lender relationship warrant close attention to future 10-Q for leverage and interest cost details. The first draw is too small to materially alter the balance sheet or cash runway outlook.

Key Facts

  • On May 26, 2026, TuHURA received its first draw of $1.7M under the $50M revolving credit facility entered into with Parkview Holdings One LLC on April 21, 2026.
  • The facility matures on April 21, 2031.
  • Proceeds are expected to be used for general corporate purposes.
  • The lender, Parkview Holdings One LLC, is an affiliate of the Company's largest stockholder (per risk factor language in the filing).

Financial Impact

First draw of $1.7M; total facility capacity is $50M. No pricing terms (interest rate, fees) or specific financial covenants disclosed in this filing.

debtliquiditycapital resources

Risk Factors

  • Related-party lender (affiliate of largest stockholder) introduces potential for conflicts of interest or unfavorable terms.
  • Future draws could substantially increase leverage and interest burden.
  • The $1.7M draw may be insufficient to fund operations if cash burn is high, necessitating additional capital raises or more draws.
  • Forward-looking statements note risk that facility may be insufficient to fund operations and development programs as anticipated.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-248640
Document: 0001193125-26-248640-index-headers.html0001193125-26-248640
Document: 0001193125-26-248640-index.html0001193125-26-248640
Document: 0001193125-26-248640.txt0001193125-26-248640
6 reports for HURA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for HURA — sortable, filterable
Type Now
May 29, 2026
11d ago
8-K
NEUTRAL ★ 4/10
$2.24 $1.97▼ −12.28%▼ −9.53%$2.05 (−8.71%)
May 15, 2026
25d ago
8-K
NEUTRAL ★ 4/10
$2.55 $2.45▼ −3.92%▼ −5.54%$2.05 (−19.80%)
Apr 22, 2026
6w ago
8-K
MIXED ★ 7/10
$2.68 $2.15▼ −19.96%▼ −20.02%$2.05 (−23.69%)
Apr 8, 2026
8w ago
424B5
BEARISH ★ 7/10
$1.96 $2.96▼ −51.02%▼ −47.83%$2.05 (−4.34%)
Apr 8, 2026
8w ago
8-K
NEUTRAL ★ 5/10
$1.96 $2.96▲ +51.02%▲ +47.83%$2.05 (+4.34%)
Apr 1, 2026
9w ago
8-K
BEARISH ★ 7/10
$1.62 $1.96▼ −20.99%▼ −17.22%$2.05 (−26.23%)
Showing 6 of 6

US Market Status

Market Closed — Opens in 3h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access